| Literature DB >> 36204332 |
Ling Gao1,2, Wenjie Ma1, Zhaoxin Lu1, Jinzhi Han1, Zhi Ma1, Hongxia Liu1, Xiaomei Bie1.
Abstract
Nonribosomal peptide synthase (NRPS) is a unique molecular assembly mechanism with high hybridity. Its recombination is conducive to the development of novel lipopeptides. However, there are few reports on NRPS subunit recombination of plipastatin at present. In this paper, plipastatin synthase was modified by the forward movement of subunit PPSE and the replacement of the communication-mediating (COM) domain. The results showed that ppsABE, a new assembly line, could synthesize novel lipopeptides such as cycle pentapeptide (C16-18β-OHFA-E-O-cyclo(Y-T-I), and its antimicrobial activity against Rhizopus stolonifer and Staphylococcus aureus was better than that of plipastatin. However, the reactivity of ppsABCE disappeared, but the substitution of COMD ppsC/COMA ppsD or COMD ppsD/COMA ppsE for COMD ppsC/COMA ppsE could restore its activity and conduct the biosynthesis of linear hexapeptide (C16-17β-OHFA-E-O-Y-T-E-A/V) and heptapeptide (C17-18β-OHFA-E-O-Y-T-E-A-I). Collectively, these findings indicated that the COM donor domain at the C-terminus of PPSB could communicate with the COM acceptor domain at the N-terminus of PPSE and that the compatible COM domain is an important tool for communication between nonpartner subunits. Moreover, the integrity and selective compatibility of the COM acceptor domain of subunit PPSE are essential to promote the interaction between PPSE and other subunits. This work further complemented the rules of NRPS subunit recombination and provided a theoretical basis for the development of novel high-efficiency lipopeptides.Entities:
Keywords: Antimicrobial activity; COM domain; Compatibility; Novel lipopeptides; Plipastatin; Subunit translocation
Year: 2022 PMID: 36204332 PMCID: PMC9519435 DOI: 10.1016/j.synbio.2022.09.001
Source DB: PubMed Journal: Synth Syst Biotechnol ISSN: 2405-805X
Fig. 1Schematic representation of subunit PPSE translocation in plipastatin synthetases.(A) Plipastatin synthase operon; (B) COM domain between synthase subunits; (C) Strategy of subunit PPSE translocation.
Plipastatin analogues produced by mutant strains.
| Strains | Mass ions (m/z) | Peptide sequence | Products |
|---|---|---|---|
| pB2-L | 1435.8, 1449.8, 1463.8, 1477.8, | C14-21 β-OHFA-E-O-Cyclo(Y-T-E-A/V–P-Q-Y-I/V) | Plipastatin |
| LP7 | 875.55, 889.57, 903.58 | C16-18 β-OHFA-E-O-cyclo(Y-T-I) | Cycle pentapeptide |
| LP8 | – | – | – |
| LP9 | 980.5435, 994.5923, 1008.5950, | C16-17 β-OHFA-E-O-Y-T-E-A/V | Linear hexapeptide |
| LP10 | 980.5435, 994.5923, 1008.5950, | C16-17 β-OHFA-E-O-Y-T-E-A/V | Linear hexapeptide |
Fig. 2ESI-MS/MS spectrum of plipastatin analogues isolated from LP7.(A) ESI-MS spectrum of plipastatin analogues isolated from mutant strain LP7; (B) ESI-MS/MS spectrum of [M+H]+ ions at 903.58 m/z.
Fig. 3Substitution strategy and sequence alignment of COM domain.(A) Schematic diagram of swapping the COM domain between subunit PPSC and PPSE in novel hybrid synthetases; (B) Sequence alignment of donor and acceptor domain derived from the plipastatin biosynthetic system. The box indicates the site of COM domain replacement.
Fig. 4High-resolution ESI-MS/MS spectrum of plipastatin derivatives isolated from LP9.(A) High-resolution ESI-MS spectrum of plipastatin derivatives isolated from mutant strain LP9; (B) MS/MS spectrum of [M+H]+ ions at 1022.61 m/z.
Fig. 5LC-ESI-MS chromatogram of crude extract lipopeptides isolated from mutant strain LP10.
Fig. 6MS/MS spectrum of [M+H]+ ions at 1121.6705 m/z isolated from mutant strain LP10.
Fig. 7Antimicrobial activity of fermentation products of mutant strains.